A Study of M207 With Intranasal Zolmitriptan in Healthy Volunteers
Status:
Completed
Trial end date:
2018-11-20
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label, randomized, four-way crossover study. Each subject will
receive each of the four study treatments once, followed by in-clinic monitoring and
extensive blood sample collection for pharmacokinetic analysis.
Dosing will occur approximately 48 hours apart, until completion of dosing in randomized
order per the treatment sequence tables. Plasma samples from the dosing days will be sent to
the analytical laboratory for analysis and tolerability for each of the dose levels will be
summarized.
After completion of the four dosing days, subjects will be assessed one final time and
dismissed from the study.